Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Favorable Outcomes with Bridging Radiation Therapy Prior to Anti-CD19 Chimeric Antigen Receptor T-Cell CART in B Cell Lymphoma, a Report from Saudi Arabia

Blood (2024) 144 (Supplement 1): 7754.

https://doi.org/10.1182/blood-2024-202399

Published: 2024

Journal Articles

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Blood (2024) 144 (Supplement 1): 7418.

https://doi.org/10.1182/blood-2024-206153

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

Prognostic Impact of CD19 Status Pre-Lymphodepletion in Anti-CD19 CAR-T Therapy for B-Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 7153.

https://doi.org/10.1182/blood-2024-207988

Published: 2024

Journal Articles

Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia

Blood (2024) 144 (Supplement 1): 7824.

https://doi.org/10.1182/blood-2024-203769

Published: 2024

Journal Articles

First Description of New Variant of Germline ERCC6L2 Mutations Causing Bone Marrow Failure, a Single Center Report of 11 Cases in 7 Families

Alfadil Haroon, Abdullah Aljefri, Mohamed Jaradi, Ahmad S. Alotaibi, Mansour Alfayez, Hazza Alzahrani, Fahad Almohareb, Ali D Alahmari, Ayman Saad, Walid Rasheed, Fahad Z. Alsharif, Naeem A. Chaudhri, Haitham A. Khogeer, Abdullah Alsuwaidan, Mahmoud Aljurf, Syed Osman Ahmed

Blood (2024) 144 (Supplement 1): 5706.

https://doi.org/10.1182/blood-2024-193282

Published: 2024

Journal Articles

Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Patients Receiving Inotuzumab Ozogamicin Followed By Total Body Irradiation-Based Conditioning for Stem Cell Transplantation: A Risk Mitigation Strategy

Ahmed Alahmadi, Abdulrahman Nasiri, Sarah Samarkandi, Haya Alothaimeen, Marwa Nassar, Ali Alahmari, Ahmad S. Alotaibi, Mansour Alfayez, Hanan Alkhaldi, Ayman Saad, Syed Osman Ahmed, Amr Hanbali

Blood (2024) 144 (Supplement 1): 7306.

https://doi.org/10.1182/blood-2024-200803

Published: 2024

Journal Articles

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Eshrak Al-Shaibani, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Muhned Alhumaid, Hanan Alkhaldi, Ayman Saad, Francesca Biavasco, Robert Zeiser, Joon Ho Moon, Sang Kyun Sohn, Jonas Mattsson, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2024-211761

Published: 2024

Journal Articles

Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Blood (2024) 144 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2024-207937

Published: 2024

Journal Articles

The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience

Reem Alasbali, Abdulrahman Nasiri, Alfadil Adam, Saud Alhayli, Naeem A. Chaudhri, Alfadel Alshaibani, Abdulwahab Albabtain, Hadeel Samarkandi, Ayman Saad, Abdullah Alamer, Tusneem Ahmed M Elhassan, Hazza A. Alzahrani, Syed Osman Ahmed, Walid Rasheed, Riad Elfakih, Mahmoud Aljurf, ALI D Alahmari

Blood (2023) 142 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2023-182580

Published: 2023

Journal Articles

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Reem Alasbali, Mohsen Alzahrani, Saud Alhayli, Walid Rasheed, Phavina Akhom, Karina Wilkerson, Mohammed Essa, Riad Elfakih, Bader Alahmari, Hadeel Samarkandi, Syed Osman Ahmed, Ayman Saad, Hazza A. Alzahrani, Fahad Almohareb, Mahmoud Aljurf, Adetola A. Kassim, Ali D Alahmari

Blood (2023) 142 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2023-189914

Published: 2023

Journal Articles

Superior Outcome of Bone Marrow Transplantation Using Fludarabine and Cyclophosphamide with ATG over Fludarabine and Cyclophosphamide without ATG Conditioning Regimen in Severe Aplastic Anemia

Blood (2023) 142 (Supplement 1): 6951.

https://doi.org/10.1182/blood-2023-182333

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplantation in Adolescent and Adult Patients with Acute T Cell Lymphoblastic Leukemia / Lymphoma : Single Center Experience of 143 Patients

Blood (2023) 142 (Supplement 1): 7101.

https://doi.org/10.1182/blood-2023-185676

Published: 2023

Journal Articles

Blinatumomab with Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review

Blood (2023) 142 (Supplement 1): 5889.

https://doi.org/10.1182/blood-2023-180221

Published: 2023

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

Molecular Characterisation and Outcomes of 363 Adolescent and Young Adults with AML in Saudi Arabia Risk Stratified By PCR and NGS-Based Testing

Blood (2023) 142 (Supplement 1): 7433.

https://doi.org/10.1182/blood-2023-187940

Published: 2023

Journal Articles

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Blood (2022) 140 (24): 2533–2548.

https://doi.org/10.1182/blood.2022015790

Published: 2022

Includes: Supplemental data

Journal Articles

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Vijaya Raj Bhatt, Valerie K Shostrom, Ayman Saad, Betty K. Hamilton, Krishna Gundabolu, Lori Maness, Virender Kumar, Ram I Mahato, Lynette M. Smith, Taiga Nishihori, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 1379–1380.

https://doi.org/10.1182/blood-2022-156340

Published: 2022

Journal Articles

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Amandeep Salhotra, Samer A Srour, Rasmus T Hoeg, Ayman Saad, Everett H Meyer, Anna Pavlova, Edmund K. Waller, Mwe Mwe Chao, J Scott McClellan, Nathaniel B Fernhoff, Robert Lowsky, Mehrdad Abedi

Blood (2022) 140 (Supplement 1): 1865–1866.

https://doi.org/10.1182/blood-2022-170459

Published: 2022

Journal Articles

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Blood (2022) 140 (Supplement 1): 1885–1886.

https://doi.org/10.1182/blood-2022-169336

Published: 2022

NARROW

Favorable Outcomes with Bridging Radiation Therapy Prior to Anti-CD19 Chimeric Antigen Receptor T-Cell CART in B Cell Lymphoma, a Report from Saudi Arabia

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Prognostic Impact of CD19 Status Pre-Lymphodepletion in Anti-CD19 CAR-T Therapy for B-Acute Lymphoblastic Leukemia

Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia

First Description of New Variant of Germline ERCC6L2 Mutations Causing Bone Marrow Failure, a Single Center Report of 11 Cases in 7 Families

Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Patients Receiving Inotuzumab Ozogamicin Followed By Total Body Irradiation-Based Conditioning for Stem Cell Transplantation: A Risk Mitigation Strategy

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Superior Outcome of Bone Marrow Transplantation Using Fludarabine and Cyclophosphamide with ATG over Fludarabine and Cyclophosphamide without ATG Conditioning Regimen in Severe Aplastic Anemia

Allogeneic Stem Cell Transplantation in Adolescent and Adult Patients with Acute T Cell Lymphoblastic Leukemia / Lymphoma : Single Center Experience of 143 Patients

Blinatumomab with Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Molecular Characterisation and Outcomes of 363 Adolescent and Young Adults with AML in Saudi Arabia Risk Stratified By PCR and NGS-Based Testing

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only